STAT+: A biotech hedge fund births a new immunology company

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Two years ago, Mohit Gupta, an analyst who works for Adar1 Capital’s Dan Schneeberger, walked into Schneeberger’s Austin, Texas, office and pitched an idea to build from the ground up a new company to develop a better, long-acting antibody treatment for atopic dermatitis. Schneeberger’s day job, of course, is to invest in biotech companies that are already developing drugs, not start one on his own. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe